|
|
Safety & Watchlist
Reliable picks + red flags
|
|
Safe Pick
|
|
JNJ64 Straight Years of Raises — and JNJ Goes Ex-Dividend Tuesday
|
Johnson & Johnson just keeps doing its thing. In April, the board raised the quarterly dividend 3.1% to $1.34 per share — that's $5.36 per year. It was the 64th consecutive annual increase, putting J&J firmly in Dividend King territory — a title reserved for companies that have raised their dividend for at least 50 straight years. Fewer than 60 public companies in America qualify.
At today's price around $273, the yield is approximately 1.96%. Put $10,000 in and you'd collect about $196 per year — roughly $49 every quarter.
Here's why JNJ earns the safe pick label right now: the payout ratio sits around 60%, which means the dividend is well-covered by earnings. After spinning off its consumer health division (now Kenvue) in 2023, J&J is a focused pharmaceutical and medical device company. Products like Darzalex and Tremfya generate high-margin revenue that funds the dividend with room to spare.
The ex-dividend date is Tuesday, August 25. If you want to collect the next $1.34, you need to own shares by Monday, August 24. Payment hits September 8.
|
|
Yield: 1.96%
|
$10K invested = $196/yr
|
Paid: Quarterly
|
|
|
|
Red Flag
|
|
PFEPfizer's 6.4% Yield Looks Great Until You See the Payout Ratio
|
I see Pfizer on nearly every high-yield screen I run. At around 6.4%, the yield sits well above what you'd get from most large-cap stocks. On $10,000, that would be $640 a year. Looks great on paper.
But here's what the yield isn't telling you. In fiscal 2025, Pfizer paid out $9.8 billion in dividends. The company generated $9.1 billion in free cash flow — that's the actual cash the business produces after paying all its bills and reinvesting in itself. Pfizer paid more in dividends than it made. The GAAP payout ratio hit 126.5%.
Think of it like this: if you earn $4,000 a month but write $5,000 in checks, you're dipping into savings. That works for a while — but not forever.
Pfizer is counting on new drug launches to ramp revenue and bring that payout back below 100%. Maybe the cancer pipeline and weight-loss treatments deliver. I genuinely don't know. But when a company's dividend costs more than its free cash flow, I want to see a clear path back to coverage before I buy. At 126.5% payout, PFE's $0.43 quarterly dividend is a warning light, not a buy signal.
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Don't miss these ex-dates: Walmart (WMT) goes ex-dividend tomorrow, August 21 — today is your last day to buy for the $0.2475 quarterly payment. Johnson & Johnson (JNJ) goes ex Tuesday, August 25 at $1.34/share — buy by Monday, August 24.
|
|
I ran a screen this morning: S&P 500 stocks with payout ratios under 25% and at least 10 consecutive years of dividend increases. Mastercard's 19% was the lowest I found among 15-year-plus streaks. Low payout ratios are the clearest sign a dividend has room to keep growing.
|
|
Someone asked me: "What's yield on cost?" It's the dividend yield based on what you paid for a stock — not today's market price. Buy FAST at $52 and if the dividend doubles over the next decade, your yield on cost is 4% even though the market still shows 2%. It's how compounders build your income without you lifting a finger.
|
|
|
|
The Dispatch
|
|
FAST sells bolts and has raised its dividend to $0.26 per quarter — growth rate of 12% a year. MA sits on a 19% payout ratio with 15 years of 15% annual growth behind it. JNJ goes ex-dividend Tuesday — 64 straight years, $1.34 per share. And Pfizer's 126% payout ratio means that tempting 6.4% yield is living on borrowed time. Tomorrow I'll have the weekly roundup — the best pick from every section, all in one place. See you then.
|
|
— Charlie
|
|
|
|